Bone marrow transplantation for lysosomal storage disorders

References

• Jansen J, Thompson JM, Dugan MJ et al. Peripheral blood progenitor cell transplantation. Ther. Apher.6, 5–14 (2002).
   PubMedGoogle Scholar
• Barker JN, Wagner JE. Umbilical cord blood transplantation: current state of the art. Curr. Opin. Oncol.14, 160–164 (2002).
   PubMed Web of Science ®Google Scholar
• De Duve C, Pressman BC, Gianetto R, Wattiaux R, Appelmans F. Tissue fractionation studies, 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem. J.60, 604–617 (1955).
   PubMed Web of Science ®Google Scholar
• Reitman ML, Kornfeld S. UDP-N-acetylglucosamine:glycoprotein N-acetylglucosamine-1-phosphotransferase. Proposed enzyme for the phosphorylation of the high mannose oligosaccharide units of lysosomal enzymes. J. Biol. Chem.256, 4275–4281 (1981).
   PubMed Web of Science ®Google Scholar
• Varki A, Kornfeld S. Purification and characterization of rat liver α-N-acetylglucosaminyl phosphodiesterase. J. Biol. Chem.256, 9937–9943 (1981).
   PubMed Web of Science ®Google Scholar
• Waheed A, Hasilik A, von Figura K. Processing of the phosphorylated recognition marker in lysosomal enzymes. Characterization and partial purification of a microsomal α-N-acetylglucosaminyl phosphodiesterase. J. Biol. Chem.256, 5717–5721 (1981).
   PubMed Web of Science ®Google Scholar
• Vladutiu GD, Rattazzi MC. Excretion-reuptake route of β-hexosaminidase in normal and I-cell disease cultured fibroblasts. J. Clin. Invest.63, 595–601 (1979).
   PubMed Web of Science ®Google Scholar
• Muschol N, Matzner U, Tiede S, Gieselmann V, Ullrich K, Braulke T. Secretion of phosphomannosyl-deficient arylsulphatase A and cathepsin D from isolated human macrophages. Biochem. J.368, 845–853 (2002).
   PubMed Web of Science ®Google Scholar
• Ling EA, Wong WC. The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia7, 9–18 (1993).
   PubMed Web of Science ®Google Scholar
• Walkley SU, Thrall MA, Dobrenis K et al. Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease. Proc. Natl Acad. Sci. USA91, 2970–2974 (1994).
   PubMed Web of Science ®Google Scholar
• Taylor RM, Wolfe JH. Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of β-glucuronidase. Nature Med.3, 771–774 (1997).
   PubMed Web of Science ®Google Scholar
• Passini MA, Lee EB, Heuer GG, Wolfe JH. Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J. Neurosci.22, 6437–6446 (2002).
   PubMed Web of Science ®Google Scholar
• Kniesel U, Risau W, Wolburg H. Development of blood-brain barrier tight junctions in the rat cortex. Brain Res. Dev. Brain Res.96, 229–240 (1996).
   PubMedGoogle Scholar
• Kniesel U, Wolburg H. Tight junctions of the blood–brain barrier. Cell Mol. Neurobiol.20, 57–76 (2000).
   PubMed Web of Science ®Google Scholar
• Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol.40, 648–677 (1969).
   PubMed Web of Science ®Google Scholar
• Lossinsky AS, Shivers RR. Studies of cerebral endothelium by scanning and high-voltage electron microscopy. Methods Mol. Med.89, 67–82 (2003).
   PubMedGoogle Scholar
• Suzuki K. Twenty five years of the “psychosine hypothesis”: a personal perspective of its history and present status. Neurochem. Res.23, 251–259 (1998).
   PubMed Web of Science ®Google Scholar
• Miyatake T, Suzuki K. Globoid cell leukodystrophy: additional deficiency of psychosine galactosidase. Biochem. Biophys. Res. Commun.48, 539–543 (1972).
   PubMedGoogle Scholar
• Toda K, Kobayashi T, Goto I et al. Lysosulfatide (sulfogalactosylsphingosine) accumulation in tissues from patients with metachromatic leukodystrophy. J. Neurochem.55, 1585–1591 (1990).
   PubMed Web of Science ®Google Scholar
• Neuenhofer S, Conzelmann E, Schwarzmann G, Egge H, Sandhoff K. Occurrence of lysoganglioside lyso-GM2 (II3-Neu5Ac-gangliotriaosylsphingosine) in GM2 gangliosidosis brain. Biol. Chem. Hoppe. Seyler.367, 241–244 (1986).
   PubMed Web of Science ®Google Scholar
• Korkotian E, Schwarz A, Pelled D, Schwarzmann G, Segal M, Futerman AH. Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J. Biol. Chem.274, 21673–21678 (1999).
   PubMed Web of Science ®Google Scholar
• Pelled D, Trajkovic-Bodennec S, Lloyd-Evans E, Sidransky E, Schiffmann R, Futerman AH. Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol. Dis.18, 83–88 (2005).
   PubMed Web of Science ®Google Scholar
• Pelled D, Lloyd-Evans E, Riebeling C, Jeyakumar M, Platt FM, Futerman AH. Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin. J. Biol. Chem.278, 29496–29501 (2003).
   PubMed Web of Science ®Google Scholar
• Gieselmann V, Franken S, Klein D et al. Metachromatic leukodystrophy: consequences of sulphatide accumulation. Acta Paediatr.92(Suppl.), 74–79 (2003).
   Web of Science ®Google Scholar
• Simonaro CM, Haskins ME, Schuchman EH. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab. Invest.81, 1319–1328 (2001).
   PubMed Web of Science ®Google Scholar
• Boot RG, Verhoek M, de Fost M et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood103, 33–39 (2004).
   PubMed Web of Science ®Google Scholar
• Boven LA, van Meurs M, Boot RG et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am. J. Clin. Pathol.122, 359–369 (2004).
   PubMed Web of Science ®Google Scholar
• Jeyakumar M, Thomas R, Elliot-Smith E et al. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain126, 974–987 (2003).
   PubMed Web of Science ®Google Scholar
• Wada R, Tifft CJ, Proia RL. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc. Natl Acad. Sci. USA97, 10954–10959 (2000).
   PubMed Web of Science ®Google Scholar
• Smits HA, Boven LA, Pereira CF, Verhoef J, Nottet HS. Role of macrophage activation in the pathogenesis of Alzheimer’s disease and human immunodeficiency virus type 1-associated dementia. Eur. J. Clin. Invest.30, 526–535 (2000).
   PubMed Web of Science ®Google Scholar
• Lloyd-Evans E, Pelled D, Riebeling C, Futerman AH. Lyso-glycosphingolipids mobilize calcium from brain microsomes via multiple mechanisms. Biochem. J.375, 561–565 (2003).
   PubMed Web of Science ®Google Scholar
• Purpura DP, Suzuki K. Distortion of neuronal geometry and formation of aberrant synapses in neuronal storage disease. Brain Res.116, 1–21 (1976).
   PubMed Web of Science ®Google Scholar
• Walkley SU. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin. Cell Dev. Biol.15, 433–444 (2004).
   PubMed Web of Science ®Google Scholar
• Conzelmann E, Sandhoff K. Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev. Neurosci.6, 58–71 (1983).
   PubMed Web of Science ®Google Scholar
• Unger ER, Sung JH, Manivel JC, Chenggis ML, Blazar BR, Krivit W. Male donor-derived cells in the brains of female sex-mismatched bone marrow transplant recipients: a Y-chromosome specific in situ hybridization study. J. Neuropathol. Exp. Neurol.52, 460–470 (1993).
   PubMed Web of Science ®Google Scholar
• Kennedy DW, Abkowitz JL. Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood90, 986–993 (1997).
   PubMed Web of Science ®Google Scholar
• Hickey WF. Leukocyte traffic in the central nervous system: the participants and their roles. Semin. Immunol.11, 125–137 (1999).
   PubMed Web of Science ®Google Scholar
• Hobbs JR, Hugh-Jones K, Barrett AJ et al. Reversal of clinical features of Hurler’s disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet2, 709–712 (1981).
   PubMed Web of Science ®Google Scholar
• Souillet G, Guffon N, Maire I et al. Outcome of 27 patients with Hurler’s syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant31, 1105–1117 (2003).
   PubMed Web of Science ®Google Scholar
• Peters C, Shapiro EG, Anderson J et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood91, 2601–2608 (1998).
   PubMed Web of Science ®Google Scholar
• Vellodi A, Young EP, Cooper A et al. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch. Dis. Child.76, 92–99 (1997).
   PubMed Web of Science ®Google Scholar
• Whitley CB, Belani KG, Chang PN et al. Long-term outcome of Hurler syndrome following bone marrow transplantation. Am. J. Med. Genet.46, 209–218 (1993).
   PubMed Web of Science ®Google Scholar
• Grewal SS, Krivit W, DeFor TE et al. Outcome of second hematopoietic cell transplantation in Hurler syndrome. Bone Marrow Transplant29, 491–496 (2002).
   PubMed Web of Science ®Google Scholar
• Gatzoulis MA, Vellodi A, Redington AN. Cardiac involvement in mucopolysaccharidoses: effects of allogeneic bone marrow transplantation. Arch. Dis. Child.73, 259–260 (1995).
   PubMed Web of Science ®Google Scholar
• Braunlin EA, Rose AG, Hopwood JJ, Candel RD, Krivit W. Coronary artery patency following long-term successful engraftment 14 years after bone marrow transplantation in the Hurler syndrome. Am. J. Cardiol.88, 1075–1077 (2001).
   PubMed Web of Science ®Google Scholar
• Weisstein JS, Delgado E, Steinbach LS, Hart K, Packman S. Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J. Pediatr. Orthop.24, 97–101 (2004).
   PubMed Web of Science ®Google Scholar
• Huang Y, Bron AJ, Meek KM, Vellodi A, McDonald B. Ultrastructural study of the cornea in a bone marrow-transplanted Hurler syndrome patient. Exp. Eye Res.62, 377–387 (1996).
   PubMed Web of Science ®Google Scholar
• Gullingsrud EO, Krivit W, Summers CG. Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up. Ophthalmology105, 1099–1105 (1998).
   PubMed Web of Science ®Google Scholar
• Bredehorn T, Clausen M, Duncker G, Lullmann-Rauch R. Morphological and functional changes due to drug-induced lysosomal storage of sulphated glycosaminoglycans in the rat retina. Graefes Arch. Clin. Exp. Ophthalmol.239, 788–793 (2001).
   PubMed Web of Science ®Google Scholar
• Braunlin EA, Stauffer NR, Peters CH et al. Usefulness of bone marrow transplantation in the Hurler syndrome. Am. J. Cardiol.92, 882–886 (2003).
   PubMed Web of Science ®Google Scholar
• Peters C, Balthazor M, Shapiro EG et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood87, 4894–4902 (1996).
   PubMed Web of Science ®Google Scholar
• Peters C, Shapiro EG, Krivit W. Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation. Pediatr. Transplant2, 250–253 (1998).
   PubMedGoogle Scholar
• Conway J, Dyack S, Crooks BN, Fernandez CV. Mixed donor chimerism and low level iduronidase expression may be adequate for neurodevelopmental protection in Hurler Syndrome. J. Pediatr.147, 106–108 (2005).
   PubMed Web of Science ®Google Scholar
• Grewal SS, Wynn R, Abdenur JE et al. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet. Med.7, 143–146 (2005).
   PubMed Web of Science ®Google Scholar
• Scott HS, Litjens T, Nelson PV et al. Identification of mutations in the α-l-iduronidase gene (IDUA) that cause Hurler and Scheie syndromes. Am. J. Hum. Genet.53, 973–986 (1993).
   PubMed Web of Science ®Google Scholar
• Fuller M, Brooks DA, Evangelista M, Hein LK, Hopwood JJ, Meikle PJ. Prediction of neuropathology in mucopolysaccharidosis I patients. Mol. Genet. Metab.84, 18–24 (2005).
   PubMed Web of Science ®Google Scholar
• Bergstrom SK, Quinn JJ, Greenstein R, Ascensao J. Long-term follow-up of a patient transplanted for Hunter’s disease type IIB: a case report and literature review. Bone Marrow Transplant14, 653–658 (1994).
   PubMed Web of Science ®Google Scholar
• Coppa GV, Gabrielli O, Zampini L et al. Bone marrow transplantation in Hunter syndrome (mucopolysaccharidosis type II): two-year follow-up of the first Italian patient and review of the literature. Pediatr. Med. Chir.17, 227–235 (1995).
   PubMedGoogle Scholar
• Coppa GV, Gabrielli O, Cordiali R, Villani GR, Di Natale P. Bone marrow transplantation in a Hunter patient with P266H mutation. Int. J. Mol. Med.4, 433–436 (1999).
   PubMed Web of Science ®Google Scholar
• McKinnis EJ, Sulzbacher S, Rutledge JC, Sanders J, Scott CR. Bone marrow transplantation in Hunter syndrome. J. Pediatr.129, 145–148 (1996).
   PubMed Web of Science ®Google Scholar
• Miniero R, Busca A, Vassallo E, Madon E. Use of G-CSF in a patient with Hunter syndrome receiving bone marrow transplantation. Am. J. Hematol.47, 59–60 (1994).
   PubMedGoogle Scholar
• Mullen CA, Thompson JN, Richard LA, Chan KW. Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia. Bone Marrow Transplant25, 1093–1097 (2000).
   PubMed Web of Science ®Google Scholar
• Peters C, Krivit W. Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome). Bone Marrow Transplant25, 1097–1099 (2000).
   PubMed Web of Science ®Google Scholar
• Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE. Long-term follow-up following bone marrow transplantation for Hunter disease. J. Inherit. Metab. Dis.22, 638–648 (1999).
   PubMed Web of Science ®Google Scholar
• Young ID, Harper PS. The natural history of the severe form of Hunter’s syndrome: a study based on 52 cases. Dev. Med. Child Neurol.25, 481–489 (1983).
   PubMed Web of Science ®Google Scholar
• Sivakumur P, Wraith JE. Bone marrow transplantation in mucopolysaccharidosis type IIIA: a comparison of an early treated patient with his untreated sibling. J. Inherit. Metab. Dis.22, 849–850 (1999).
   PubMed Web of Science ®Google Scholar
• Vellodi A, Young E, New M, Pot-Mees C, Hugh-Jones K. Bone marrow transplantation for Sanfilippo disease type B. J. Inherit. Metab. Dis.15, 911–918 (1992).
   PubMed Web of Science ®Google Scholar
• Ford-Perriss M, Turner K, Guimond S et al. Localisation of specific heparan sulfate proteoglycans during the proliferative phase of brain development. Dev. Dyn.227, 170–184 (2003).
   PubMed Web of Science ®Google Scholar
• Guimond S, Turner K, Kita M, Ford-Perriss M, Turnbull J. Dynamic biosynthesis of heparan sulphate sequences in developing mouse brain: a potential regulatory mechanism during development. Biochem. Soc. Trans.29, 177–181 (2001).
   PubMed Web of Science ®Google Scholar
• Inatani M, Irie F, Plump AS, Tessier-Lavigne M, Yamaguchi Y. Mammalian brain morphogenesis and midline axon guidance require heparan sulfate. Science302, 1044–1046 (2003).
   PubMed Web of Science ®Google Scholar
• Li HH, Zhao HZ, Neufeld EF, Cai Y, Gomez-Pinilla F. Attenuated plasticity in neurons and astrocytes in the mouse model of Sanfilippo syndrome type B. J. Neurosci.Res.69, 30–38 (2002).
   Web of Science ®Google Scholar
• Walkley SU, Thrall MA, Haskins ME et al. Abnormal neuronal metabolism and storage in mucopolysaccharidosis type VI (Maroteaux-Lamy) disease. Neuropathol. Appl. Neurobiol.31, 536–544 (2005).
   PubMed Web of Science ®Google Scholar
• Herskhovitz E, Young E, Rainer J et al. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up. J. Inherit. Metab. Dis.22, 50–62 (1999).
   PubMed Web of Science ®Google Scholar
• Harmatz P, Whitley CB, Waber L et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J. Pediatr.144, 574–580 (2004).
   PubMed Web of Science ®Google Scholar
• Yamada Y, Kato K, Sukegawa K et al. Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant21, 629–634 (1998).
   PubMed Web of Science ®Google Scholar
• Grewal S, Shapiro E, Braunlin E et al. Continued neurocognitive development and prevention of cardiopulmonary complications after successful BMT for I-cell disease: a long-term follow-up report. Bone Marrow Transplant32, 957–960 (2003).
   PubMed Web of Science ®Google Scholar
• Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant30, 215–222 (2002).
   PubMed Web of Science ®Google Scholar
• Koc ON, Peters C, Aubourg P et al. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp. Hematol.27, 1675–1681 (1999).
   PubMed Web of Science ®Google Scholar
• Byers S, Crawley AC, Brumfield LK, Nuttall JD, Hopwood JJ. Enzyme replacement therapy in a feline model of MPS VI: modification of enzyme structure and dose frequency. Pediatr. Res.47, 743–749 (2000).
   PubMed Web of Science ®Google Scholar
• Kanaji A, Kosuga M, Li XK, Fukuhara Y et al. Improvement of skeletal lesions in mice with mucopolysaccharidosis type VII by neonatal adenoviral gene transfer. Mol. Ther.8, 718–725 (2003).
   PubMed Web of Science ®Google Scholar
• Dhuna A, Toro C, Torres F, Kennedy WR, Krivit W. Longitudinal neurophysiologic studies in a patient with metachromatic leukodystrophy following bone marrow transplantation. Arch. Neurol.49, 1088–1092 (1992).
   PubMedGoogle Scholar
• Groth CG, Ringden O. Transplantation in relation to the treatment of inherited disease. Transplantation38, 319–327 (1984).
   PubMed Web of Science ®Google Scholar
• Guffon N, Souillet G, Maire I, Dorche C, Mathieu M, Guibaud P. Juvenile metachromatic leukodystrophy: neurological outcome two years after bone marrow transplantation. J. Inherit. Metab. Dis.18, 159–161 (1995).
   PubMed Web of Science ®Google Scholar
• Kidd D, Nelson J, Jones F et al. Long-term stabilization after bone marrow transplantation in juvenile metachromatic leukodystrophy. Arch. Neurol.55, 98–99 (1998).
   PubMedGoogle Scholar
• Malm G, Ringden O, Winiarski J et al. Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow transplantation. Bone Marrow Transplant17, 1003–1008 (1996).
   PubMed Web of Science ®Google Scholar
• Navarro C, Fernandez JM, Dominguez C, Fachal C, Alvarez M. Late juvenile metachromatic leukodystrophy treated with bone marrow transplantation; a 4-year follow-up study. Neurology46, 254–256 (1996).
   PubMed Web of Science ®Google Scholar
• Pridjian G, Humbert J, Willis J, Shapira E. Presymptomatic late-infantile metachromatic leukodystrophy treated with bone marrow transplantation. J. Pediatr.125, 755–758 (1994).
   PubMed Web of Science ®Google Scholar
• Shapiro EG, Lipton ME, Krivit W. White matter dysfunction and its neuropsychological correlates: a longitudinal study of a case of metachromatic leukodystrophy treated with bone marrow transplant. J. Clin. Exp. Neuropsychol.14, 610–624 (1992).
   PubMed Web of Science ®Google Scholar
• Yazaki M, Ohno T, Matsubayashi T et al. Detection of donor lymphocytes in the cerebrospinal fluid of a patient with metachromatic leukodystrophy following bone marrow transplantation. Bone Marrow Transplant15, 137–139 (1995).
   PubMed Web of Science ®Google Scholar
• Zafeiriou DI, Kontopoulos EE, Michelakakis HM, Anastasiou AL, Gombakis NP. Neurophysiology and MRI in late-infantile metachromatic leukodystrophy. Pediatr. Neurol.21, 843–846 (1999).
   PubMed Web of Science ®Google Scholar
• Solders G, Celsing G, Hagenfeldt L, Ljungman P, Isberg B, Ringden O. Improved peripheral nerve conduction, EEG and verbal IQ after bone marrow transplantation for adult metachromatic leukodystrophy. Bone Marrow Transplant22, 1119–1122 (1998).
   PubMed Web of Science ®Google Scholar
• Landrieu P, Blanche S, Vanier MT et al. Bone marrow transplantation in metachromatic leukodystrophy caused by saposin-B deficiency: a case report with a 3-year follow-up period. J. Pediatr.133, 129–132 (1998).
   PubMed Web of Science ®Google Scholar
• Caniglia M, Rana I, Pinto RM et al. Allogeneic bone marrow transplantation for infantile globoid-cell leukodystrophy (Krabbe’s disease). Pediatr. Transplant6, 427–431 (2002).
   PubMed Web of Science ®Google Scholar
• Escolar ML, Poe MD, Provenzale JM et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe’s disease. N. Engl. J. Med.352, 2069–2081 (2005).
   PubMed Web of Science ®Google Scholar
• Krivit W, Aubourg P, Shapiro E, Peters C. Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Curr. Opin. Hematol.6, 377–382 (1999).
   PubMedGoogle Scholar
• Krivit W, Lockman LA, Watkins PA, Hirsch J, Shapiro EG. The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. J. Inherit. Metab. Dis.18, 398–412 (1995).
   PubMed Web of Science ®Google Scholar
• Shapiro EG, Lockman LA, Balthazor M, Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J. Inherit. Metab. Dis.18, 413–429 (1995).
   PubMed Web of Science ®Google Scholar
• Yagi T, Matsuda J, Tominaga K, Suzuki K, Suzuki K. Hematopoietic cell transplantation ameliorates clinical phenotype and progression of the CNS pathology in the mouse model of late onset Krabbe disease. J. Neuropathol. Exp. Neurol.64, 565–575 (2005).
   PubMed Web of Science ®Google Scholar
• Erikson A, Groth CG, Mansson JE, Percy A, Ringden O, Svennerholm L. Clinical and biochemical outcome of marrow transplantation for Gaucher disease of the Norrbottnian type. Acta Paediatr. Scand.79, 680–685 (1990).
   PubMed Web of Science ®Google Scholar
• Ringden O, Groth CG, Erikson A et al. Long-term follow-up of the first successful bone marrow transplantation in Gaucher disease. Transplantation46, 66–70 (1988).
   PubMed Web of Science ®Google Scholar
• Hobbs JR, Jones KH, Shaw PJ, Lindsay I, Hancock M. Beneficial effect of pre-transplant splenectomy on displacement bone marrow transplantation for Gaucher’s syndrome. Lancet1, 1111–1115 (1987).
   PubMed Web of Science ®Google Scholar
• Starer F, Sargent JD, Hobbs JR. Regression of the radiological changes of Gaucher’s disease following bone marrow transplantation. Br. J. Radiol.60, 1189–1195 (1987).
   PubMed Web of Science ®Google Scholar
• Shield JP, Stone J, Steward CG. Bone marrow transplantation correcting β-galactosidase activity does not influence neurological outcome in juvenile GM1-gangliosidosis. J. Inherit. Metab. Dis.28, 797–798 (2005).
   PubMed Web of Science ®Google Scholar
• Bayever E, Kamani N, Ferreira P et al. Bone marrow transplantation for Niemann-Pick type IA disease. J. Inherit. Metab. Dis.15, 919–928 (1992).
   PubMed Web of Science ®Google Scholar
• Victor S, Coulter JB, Besley GT et al. Niemann-Pick disease: sixteen-year follow-up of allogeneic bone marrow transplantation in a type B variant. J. Inherit. Metab. Dis.26, 775–785 (2003).
   PubMed Web of Science ®Google Scholar
• Shah AJ, Kapoor N, Crooks GM et al. Successful hematopoietic stem cell transplantation for Niemann-Pick disease type B. Pediatrics116, 1022–1025 (2005).
   PubMed Web of Science ®Google Scholar
• Dhami R, Schuchman EH. Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy. J. Biol. Chem.279, 1526–1532 (2004).
   PubMed Web of Science ®Google Scholar
• Vanier MT, Millat G. Structure and function of the NPC2 protein. Biochim. Biophys. Acta1685, 14–21 (2004).
   PubMed Web of Science ®Google Scholar
• Chang TY, Reid PC, Sugii S, Ohgami N, Cruz JC, Chang CC. Niemann-Pick type C disease and intracellular cholesterol trafficking. J. Biol. Chem.280, 20917–20920 (2005).
   PubMed Web of Science ®Google Scholar
• Hsu YS, Hwu WL, Huang SF et al. Niemann-Pick disease type C (a cellular cholesterol lipidosis) treated by bone marrow transplantation. Bone Marrow Transplant.24, 103–107 (1999).
   PubMed Web of Science ®Google Scholar
• Tamura H, Takahashi T, Ban N et al. Niemann-Pick type C disease: novel NPC1 mutations and characterization of the concomitant acid sphingomyelinase deficiency. Mol. Genet. Metab.87(2), 113–121 (2006).
   PubMed Web of Science ®Google Scholar
• Grewal SS, Shapiro EG, Krivit W et al. Effective treatment of α-mannosidosis by allogeneic hematopoietic stem cell transplantation. J. Pediatr.144, 569–573 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor RM, Stewart GJ, Farrow BR. Improvement in the neurologic signs and storage lesions of fucosidosis in dogs given marrow transplants at an early age. Transplant Proc.21, 3818–3819 (1989).
   PubMed Web of Science ®Google Scholar
• Miano M, Lanino E, Gatti R et al. Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation. Bone Marrow Transplant27, 747–751 (2001).
   PubMed Web of Science ®Google Scholar
• Vellodi A, Cragg H, Winchester B et al. Allogeneic bone marrow transplantation for fucosidosis. Bone Marrow Transplant15, 153–158 (1995).
   PubMed Web of Science ®Google Scholar
• Autti T, Rapola J, Santavuori P et al. Bone marrow transplantation in aspartylglucosaminuria – histopathological and MRI study. Neuropediatrics30, 283–288 (1999).
   PubMed Web of Science ®Google Scholar
• Harkke S, Laine M, Jalanko A. Aspartylglucosaminidase (AGA) is efficiently produced and endocytosed by glial cells: implication for the therapy of a lysosomal storage disorder. J. Gene Med.5, 472–482 (2003).
   PubMed Web of Science ®Google Scholar
• Laine M, Ahtiainen L, Rapola J, Richter J, Jalanko A. Bone marrow transplantation in young aspartylglucosaminuria mice: improved clearance of lysosomal storage in brain by using wild type as compared to heterozygote donors. Bone Marrow Transplant.34, 1001–1003 (2004).
   PubMed Web of Science ®Google Scholar
• Laine M, Richter J, Fahlman C et al. Correction of peripheral lysosomal accumulation in mice with aspartylglucosaminuria by bone marrow transplantation. Exp. Hematol.27, 1467–1474 (1999).
   PubMed Web of Science ®Google Scholar
• Krivit W, Peters C, Dusenbery K et al. Wolman disease successfully treated by bone marrow transplantation. Bone Marrow Transplant.26, 567–570 (2000).
   PubMed Web of Science ®Google Scholar
• Yeager AM, Uhas KA, Coles CD, Davis PC, Krause WL, Moser HW. Bone marrow transplantation for infantile ceramidase deficiency (Farber disease). Bone Marrow Transplant. 26, 357–363 (2000).
   PubMed Web of Science ®Google Scholar
• Vormoor J, Ehlert K, Groll AH, Koch HG, Frosch M, Roth J. Successful hematopoietic stem cell transplantation in Farber disease. J. Pediatr.144, 132–134 (2004).
   PubMed Web of Science ®Google Scholar
• Tabbara IA, Zimmerman K, Morgan C, Nahleh Z. Allogeneic hematopoietic stem cell transplantation: complications and results. Arch. Intern. Med.162, 1558–1566 (2002).
   PubMed Web of Science ®Google Scholar
• Barnes RA, Stallard N. Severe infections after bone marrow transplantation. Curr. Opin. Crit. Care7, 362–366 (2001).
   PubMedGoogle Scholar
• Vogelsang GB, Dalal J. Hepatic venoocclusive disease in blood and bone marrow transplantation in children: incidence, risk factors, and outcome. J. Pediatr. Hematol. Oncol.24, 706–709 (2002).
   PubMed Web of Science ®Google Scholar
• Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer101, 1936–1946 (2004).
   PubMed Web of Science ®Google Scholar
• Anasetti C. Advances in the prevention of graft-versus-host disease after hematopoietic cell transplantation. Transplantation77, S79–S83 (2004).
   Google Scholar
• Farag SS. Chronic graft-versus-host disease: where do we go from here? Bone Marrow Transplant33, 569–577 (2004).
   PubMed Web of Science ®Google Scholar
• Sostak P, Padovan CS, Yousry TA, Ledderose G, Kolb HJ, Straube A. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology60, 842–848 (2003).
   PubMed Web of Science ®Google Scholar
• Barton NW, Brady RO, Dambrosia JM et al. Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher disease. J. Pediatr.120, 277–280 (1992).
   PubMed Web of Science ®Google Scholar
• Clarke JT, Iwanochko RM. Enzyme replacement therapy of Fabry disease. Mol. Neurobiol.32, 43–50 (2005).
   PubMed Web of Science ®Google Scholar
• Wraith JE, Clarke LA, Beck M et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-l-iduronidase (laronidase). J. Pediatr.144, 581–588 (2004).
   PubMed Web of Science ®Google Scholar
• Urayama A, Grubb JH, Sly WS, Banks WA. Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. Proc. Natl Acad. Sci. USA101, 12658–12663 (2004).
   PubMed Web of Science ®Google Scholar
• Vogler C, Levy B, Grubb JH et al. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc. Natl Acad. Sci. USA102, 14777–14782 (2005).
   PubMed Web of Science ®Google Scholar
• Dunder U, Kaartinen V, Valtonen P et al. Enzyme replacement therapy in a mouse model of aspartylglycosaminuria. FASEB J.14, 361–367 (2000).
   PubMed Web of Science ®Google Scholar
• Matzner U, Herbst E, Hedayati KK et al. Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum. Mol. Genet.14, 1139–1152 (2005).
   PubMed Web of Science ®Google Scholar
• Elstein D, Hollak C, Aerts JM et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J. Inherit. Metab. Dis.27, 757–766 (2004).
   PubMed Web of Science ®Google Scholar
• Platt FM, Neises GR, Reinkensmeier G et al. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science276, 428–431 (1997).
   PubMed Web of Science ®Google Scholar
• Jeyakumar M, Butters TD, Cortina-Borja M et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc. Natl Acad. Sci. USA96, 6388–6393 (1999).
   PubMed Web of Science ®Google Scholar
• Jeyakumar M, Norflus F, Tifft CJ et al. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood97, 327–329 (2001).
   PubMed Web of Science ®Google Scholar
• Kasperzyk JL, D’Azzo A, Platt FM, Alroy J, Seyfried TN. Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice. J. Lipid Res.46(4), 744–751 (2005).
   PubMed Web of Science ®Google Scholar
• Cheng SH, Smith AE. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther.10, 1275–1281 (2003).
   PubMed Web of Science ®Google Scholar
• D’Azzo A. Gene transfer strategies for correction of lysosomal storage disorders. Acta Haematol.110, 71–85 (2003).
   PubMed Web of Science ®Google Scholar
• Ioannou YA, Enriquez A, Benjamin C. Gene therapy for lysosomal storage disorders. Exp. Opin. Biol. Ther.3, 789–801 (2003).
   PubMed Web of Science ®Google Scholar
• Biffi A, De Palma M, Quattrini A et al. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J. Clin. Invest.113, 1118–1129 (2004).
   PubMed Web of Science ®Google Scholar
• Zhou XY, Morreau H, Rottier R et al. Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with overexpressing erythroid precursor cells. Genes Dev.9, 2623–2634 (1995).
   PubMed Web of Science ®Google Scholar
• Vogler C, Galvin N, Levy B et al. Transgene produces massive overexpression of human β-glucuronidase in mice, lysosomal storage of enzyme, and strain-dependent tumors. Proc. Natl Acad. Sci. USA100, 2669–2673 (2003).
   PubMed Web of Science ®Google Scholar
• Desmaris N, Verot L, Puech JP, Caillaud C, Vanier MT, Heard JM. Prevention of neuropathology in the mouse model of Hurler syndrome. Ann. Neurol.56, 68–76 (2004).
   PubMed Web of Science ®Google Scholar
• Brooks AI, Stein CS, Hughes SM et al. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc. Natl Acad. Sci. USA99, 6216–6221 (2002).
   PubMed Web of Science ®Google Scholar
• Cressant A, Desmaris N, Verot L et al. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J. Neurosci.24, 10229–10239 (2004).
   PubMed Web of Science ®Google Scholar
• Frisella WA, O’Connor LH, Vogler CA et al. Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Mol. Ther.3, 351–358 (2001).
   PubMed Web of Science ®Google Scholar
• Bosch A, Perret E, Desmaris N, Trono D, Heard JM. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum.Gene Ther.11, 1139–1150 (2000).
   Google Scholar
• Crystal RG, Sondhi D, Hackett NR et al. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum. Gene Ther.15, 1131–1154 (2004).
   PubMed Web of Science ®Google Scholar
• Terada N, Hamazaki T, Oka M et al. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature416, 542–545 (2002).
   PubMed Web of Science ®Google Scholar
• Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature418, 41–49 (2002).
   PubMed Web of Science ®Google Scholar
• Ying QL, Nichols J, Evans EP, Smith AG. Changing potency by spontaneous fusion. Nature416, 545–548 (2002).
   PubMed Web of Science ®Google Scholar
• O’Brien JS, Storb R, Raff RF et al. Bone marrow transplantation in canine GM1 gangliosidosis. Clin. Genet.38, 274–280 (1990).
   PubMed Web of Science ®Google Scholar
• Hoogerbrugge PM, Suzuki K, Suzuki K et al. Donor-derived cells in the central nervous system of twitcher mice after bone marrow transplantation. Science239, 1035–1038 (1988).
   PubMed Web of Science ®Google Scholar
• Yeager AM, Brennan S, Tiffany C, Moser HW, Santos GW. Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse. Science225, 1052–1054 (1984).
   PubMed Web of Science ®Google Scholar
• Ohshima T, Schiffmann R, Murray GJ et al. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc. Natl Acad. Sci. USA96, 6423–6427 (1999).
   PubMed Web of Science ®Google Scholar
• Breider MA, Shull RM, Constantopoulos G. Long-term effects of bone marrow transplantation in dogs with mucopolysaccharidosis I. Am. J. Pathol.134, 677–692 (1989).
   PubMed Web of Science ®Google Scholar
• Shull RM, Hastings NE, Selcer RR et al. Bone marrow transplantation in canine mucopolysaccharidosis I. Effects within the central nervous system. J. Clin. Invest.79, 435–443 (1987).
   PubMed Web of Science ®Google Scholar
• Dial SM, Byrne T, Haskins M et al. Urine glycosaminoglycan concentrations in mucopolysaccharidosis VI-affected cats following bone marrow transplantation or leukocyte infusion. Clin. Chim. Acta263, 1–14 (1997).
   PubMed Web of Science ®Google Scholar
• Gasper PW, Thrall MA, Wenger DA et al. Correction of feline arylsulphatase B deficiency (mucopolysaccharidosis VI) by bone marrow transplantation. Nature312, 467–469 (1984).
   PubMed Web of Science ®Google Scholar
• Norrdin RW, Simske SJ, Gaarde S, Schwardt JD, Thrall MA. Bone changes in mucopolysaccharidosis VI in cats and the effects of bone marrow transplantation: mechanical testing of long bones. Bone17, 485–489 (1995).
   PubMed Web of Science ®Google Scholar
• Wenger DA, Gasper PW, Thrall MA, Dial SM, LeCouteur RA, Hoover EA. Bone marrow transplantation in the feline model of arylsulfatase B deficiency. Birth Defects Orig. Artic. Ser.22, 177–186 (1986).
   PubMedGoogle Scholar
• Bastedo L, Sands MS, Lambert DT, Pisa MA, Birkenmeier E, Chang PL. Behavioral consequences of bone marrow transplantation in the treatment of murine mucopolysaccharidosis type VII. J. Clin. Invest.94, 1180–1186 (1994).
   PubMed Web of Science ®Google Scholar
• Ohlemiller KK, Vogler CA, Roberts M, Galvin N, Sands MS. Retinal function is improved in a murine model of a lysosomal storage disease following bone marrow transplantation. Exp. Eye Res.71, 469–481 (2000).
   PubMed Web of Science ®Google Scholar
• Poorthuis BJ, Romme AE, Willemsen R, Wagemaker G. Bone marrow transplantation has a significant effect on enzyme levels and storage of glycosaminoglycans in tissues and in isolated hepatocytes of mucopolysaccharidosis type VII mice. Pediatr. Res.36, 187–193 (1994).
   PubMed Web of Science ®Google Scholar
• Sammarco C, Weil M, Just C et al. Effects of bone marrow transplantation on the cardiovascular abnormalities in canine mucopolysaccharidosis VII. Bone Marrow Transplant25, 1289–1297 (2000).
   PubMed Web of Science ®Google Scholar
• Sands MS, Erway LC, Vogler C, Sly WS, Birkenmeier EH. Syngeneic bone marrow transplantation reduces the hearing loss associated with murine mucopolysaccharidosis type VII. Blood86, 2033–2040 (1995).
   PubMedGoogle Scholar
• Schuldt AJ, Hampton TJ, Chu V, Vogler CA, Galvin N, Lessard MD, Barker JE. Electrocardiographic and other cardiac anomalies in β-glucuronidase-null mice corrected by nonablative neonatal marrow transplantation. Proc. Natl Acad. Sci. USA101, 603–608 (2004).
   PubMed Web of Science ®Google Scholar
• Sakiyama T, Tsuda M, Owada M et al. Bone marrow transplantation in Niemann-Pick mice. J. Inherit. Metab. Dis.9, 305–308 (1986).
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Shulman HM, Albrechtsen D, Graham TC, Storb R, Koppang N. Batten’s disease: failure of allogeneic bone marrow transplantation to arrest disease progression in a canine model. Clin. Genet.37, 264–270 (1990).
   PubMed Web of Science ®Google Scholar
• Will A, Cooper A, Hatton C, Sardharwalla IB, Evans DI, Stevens RF. Bone marrow transplantation in the treatment of α-mannosidosis. Arch. Dis. Child.62, 1044–1049 (1987).
   PubMed Web of Science ®Google Scholar
• Krivit W, Pierpont ME, Ayaz K et al. Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation. N. Engl. J. Med.311, 1606–1611 (1984).
   PubMed Web of Science ®Google Scholar
• McGovern MM, Ludman MD, Short MP et al. Bone marrow transplantation in Maroteaux-Lamy syndrome (MPS type 6): status 40 months after BMT. Birth Defects Orig. Artic. Ser.22, 41–53 (1986).
   PubMedGoogle Scholar
• Lee V, Li CK, Shing MM et al. Umbilical cord blood transplantation for Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Bone Marrow Transplant26, 455–458 (2000).
   PubMed Web of Science ®Google Scholar
• Bayever E, Ladisch S, Philippart M et al. Bone-marrow transplantation for metachromatic leucodystrophy. Lancet2, 471–473 (1985).
   PubMed Web of Science ®Google Scholar
• Kapaun P, Dittmann RW, Granitzny B et al. Slow progression of juvenile metachromatic leukodystrophy 6 years after bone marrow transplantation. J. Child Neurol.14, 222–228 (1999).
   PubMed Web of Science ®Google Scholar
• Krivit W, Shapiro E, Kennedy W et al. Treatment of late infantile metachromatic leukodystrophy by bone marrow transplantation. N. Engl. J. Med.322, 28–32 (1990).
   PubMed Web of Science ®Google Scholar
• Krivit W, Lipton ME, Lockman LA et al. Prevention of deterioration in metachromatic leukodystrophy by bone marrow transplantation. Am. J. Med. Sci.294, 80–85 (1987).
   PubMed Web of Science ®Google Scholar
• Ladisch S, Bayever E, Philippart M, Feig SA. Biochemical findings after bone marrow transplantation for metachromatic leukodystrophy: a preliminary report. Birth Defects Orig. Artic. Ser.22, 69–76 (1986).
   PubMedGoogle Scholar
• Lipton M, Lockman LA, Ramsay NK, Kersey JH, Jacobson RI, Krivit W. Bone marrow transplantation in metachromatic leukodystrophy. Birth Defects Orig. Artic. Ser.22, 57–67 (1986).
   PubMedGoogle Scholar
• Shapiro EG, Lipton ME, Krivit W. White matter dysfunction and its neuropsychological correlates: a longitudinal study of a case of metachromatic leukodystrophy treated with bone marrow transplant. J. Clin. Exp. Neuropsychol.14, 610–624 (1992).
   PubMed Web of Science ®Google Scholar
• Stillman AE, Krivit W, Shapiro E, Lockman L, Latchaw RE. Serial MR after bone marrow transplantation in two patients with metachromatic leukodystrophy. Am. J. Neuroradiol.15, 1929–1932 (1994).
   PubMed Web of Science ®Google Scholar
• Rappeport JM, Ginns EI. Bone-marrow transplantation in severe Gaucher’s disease. N. Engl. J. Med.311, 84–88 (1984).
   PubMed Web of Science ®Google Scholar
• Ringden O, Groth CG, Erikson A, Granqvist S, Mansson JE, Sparrelid E. Ten years’ experience of bone marrow transplantation for Gaucher disease. Transplantation59, 864–870 (1995).
   PubMed Web of Science ®Google Scholar
• Svennerholm L, Erikson A, Groth CG, Ringden O, Mansson JE. Norrbottnian type of Gaucher disease – clinical, biochemical and molecular biology aspects: successful treatment with bone marrow transplantation. Dev. Neurosci.13, 345–351 (1991).
   PubMed Web of Science ®Google Scholar